Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
First-Patient-In for Ph 1 Trial of IDE574 in Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer April 7, 2026
First-Patient-In for Ph 1 Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma April 7, 2026
QUILT-2.005 randomized clinical trial on track for final analysis and supplemental BLA submission in 2026 for the BCG-naïve NMIBC carcinoma in situ March 31, 2026
First Patient dosed in Ph 1 Trial of CLIO-8221 in Advanced HER2-Expressing Solid Tumors March 31, 2026
First Patient Dosed in Ph 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma March 31, 2026
Ph 1/2 Duravelo-3 trial for zelenectide in NECTIN4-amplified breast cancer and Duravelo-4 trial in NECTIN4-amplified NSCLC to be discontinued; trial design of Duravelo-2 trial to be changed March 24, 2026
45th subject enrolled in pivotal Ph 2B/3 MIRACLE trial of Annamycin + cytarabine (AnnAraC) for R/R AML March 24, 2026
First Patient Dosed in Ph 1/2 Trial of TRI-611 for the Treatment of ALK Positive NSCLC March 24, 2026
Ph 3 trial FLAMINGO-01 of GLSI-100 to prevent breast cancer recurrences announced the initiation of new clinical sites in the US March 24, 2026
Tazverik® (tazemetostat) voluntarily withdrawn in follicular lymphoma and epithelioid sarcoma March 17, 2026
